MED PE Ratio & Valuation,Is MED Overvalued

MED Relative Valuation

MED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MED is overvalued; if below, it's undervalued.

Historical Valuation

Medifast Inc (MED) is now in the Fair zone, suggesting that its current forward PS ratio of 0.38 is considered Fairly compared with the five-year average of 11.24. The fair price of Medifast Inc (MED) is between 11.91 to 39.77 according to relative valuation methord.

Relative Value

Fair Zone

11.91-39.77

Current Price：12.00

Fair

-7.10

2.74

EV/EBITDA

Medifast Inc. (MED) has a current EV/EBITDA of 2.74. The 5-year average EV/EBITDA is 6.88. The thresholds are as follows: Strongly Undervalued below -0.74, Undervalued between -0.74 and 3.07, Fairly Valued between 10.69 and 3.07, Overvalued between 10.69 and 14.50, and Strongly Overvalued above 14.50. The current Forward EV/EBITDA of 2.74 falls within the Undervalued range.

1.22

EV/EBIT

Medifast Inc. (MED) has a current EV/EBIT of 1.22. The 5-year average EV/EBIT is 7.88. The thresholds are as follows: Strongly Undervalued below -18.28, Undervalued between -18.28 and -5.20, Fairly Valued between 20.96 and -5.20, Overvalued between 20.96 and 34.04, and Strongly Overvalued above 34.04. The current Forward EV/EBIT of 1.22 falls within the Historic Trend Line -Fairly Valued range.

0.38

Medifast Inc. (MED) has a current PS of 0.38. The 5-year average PS is 0.97. The thresholds are as follows: Strongly Undervalued below -0.13, Undervalued between -0.13 and 0.42, Fairly Valued between 1.51 and 0.42, Overvalued between 1.51 and 2.06, and Strongly Overvalued above 2.06. The current Forward PS of 0.38 falls within the Undervalued range.

0.00

P/OCF

Medifast Inc. (MED) has a current P/OCF of 0.00. The 5-year average P/OCF is 9.91. The thresholds are as follows: Strongly Undervalued below -1.76, Undervalued between -1.76 and 4.08, Fairly Valued between 15.74 and 4.08, Overvalued between 15.74 and 21.57, and Strongly Overvalued above 21.57. The current Forward P/OCF of 0.00 falls within the Undervalued range.

-8.53

P/FCF

Medifast Inc. (MED) has a current P/FCF of -8.53. The 5-year average P/FCF is 16.71. The thresholds are as follows: Strongly Undervalued below -22.07, Undervalued between -22.07 and -2.68, Fairly Valued between 36.10 and -2.68, Overvalued between 36.10 and 55.49, and Strongly Overvalued above 55.49. The current Forward P/FCF of -8.53 falls within the Undervalued range.

Medifast Inc (MED) has a current Price-to-Book (P/B) ratio of 0.59. Compared to its 3-year average P/B ratio of 2.68 , the current P/B ratio is approximately -77.91% higher. Relative to its 5-year average P/B ratio of 6.89, the current P/B ratio is about -91.42% higher. Medifast Inc (MED) has a Forward Free Cash Flow (FCF) yield of approximately 0.51%. Compared to its 3-year average FCF yield of 17.73%, the current FCF yield is approximately -97.13% lower. Relative to its 5-year average FCF yield of 12.44% , the current FCF yield is about -95.91% lower.

0.57

P/B

Median3y

2.68

Median5y

6.89

0.51

FCF Yield

Median3y

17.73

Median5y

12.44

Competitors Valuation Multiple

The average P/S ratio for MED's competitors is 0.00, providing a benchmark for relative valuation. Medifast Inc Corp (MED) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -36.21%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MED decreased by 31.90% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 116.39 to 601.35.

The secondary factor is the Revenue Growth, contributed -36.21%to the performance.

Overall, the performance of MED in the past 1 year is driven by P/E Change. Which is more unsustainable.

-36.21%

140.16M → 89.41M

Revenue Growth

-412.35%

0.81 → -2.53

Margin Expansion

416.66%

116.39 → 601.35

P/E Change

-31.90%

17.62 → 12.00

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Medifast Inc (MED) currently overvalued or undervalued?

What is Medifast Inc (MED) fair value?

MED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Medifast Inc (MED) is between 11.91 to 39.77 according to relative valuation methord.

How does MED's valuation metrics compare to the industry average?

What is the current P/B ratio for Medifast Inc (MED) as of Dec 16 2025?

As of Dec 16 2025, Medifast Inc (MED) has a P/B ratio of 0.59. This indicates that the market values MED at 0.59 times its book value.

What is the current FCF Yield for Medifast Inc (MED) as of Dec 16 2025?

As of Dec 16 2025, Medifast Inc (MED) has a FCF Yield of 0.51%. This means that for every dollar of Medifast Inc’s market capitalization, the company generates 0.51 cents in free cash flow.

What is the current Forward P/E ratio for Medifast Inc (MED) as of Dec 16 2025?

As of Dec 16 2025, Medifast Inc (MED) has a Forward P/E ratio of -7.31. This means the market is willing to pay $-7.31 for every dollar of Medifast Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Medifast Inc (MED) as of Dec 16 2025?

As of Dec 16 2025, Medifast Inc (MED) has a Forward P/S ratio of 0.38. This means the market is valuing MED at $0.38 for every dollar of expected revenue over the next 12 months.

MED Valuation